Correlation of hormone receptors with her-2 neu protein expression and the histological grade in invasive breast cancers in a cohort of saudi arabia

Arafah, Maha

doi:10.5146/tjpath.2012.01095

Cited by 10 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, the HER2-negative status was associated with positive ERα and ERβ expression. This result is concordant with previous data that demonstrated a significant negative correlation between the expression of the hormone receptor and HER2/neu amplification ( 24 , 34 , 35 ). The combination of HER2 overexpression and a high Ki-67 index has been suggested to be a prognostic molecular marker for breast cancer ( 36 ).…”

Section: Discussionsupporting

confidence: 93%

“…The optimal cutoff value was identified as 1 for the low Ki-67 expression level and >1 for high expression ( 23 ). The scoring of Her2 was performed on a 0–3 scale ( 24 ). Positive (3+) was defined as intense complete membranous staining in >30% of the tumor cell population; borderline (2+) was defined as moderate membranous staining in >10% of tumor cells; 1+ was defined as either weak or barely perceptible membranous staining in >10% of the tumor cells.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

ERα and ERβ co-expression: An indicator of aggressive tumors and hormonal sensitivity

et al. 2017

View full text Add to dashboard Cite

The estrogen receptors (ERs) ERα and ERβ are important factors in breast cancer progression. Nevertheless, the molecular interplay between ERα and ERβ and its clinical significance in breast cancer is controversial. The establishment of a clear association is required; therefore, the current study analyzed the expression patterns of ERα and ERβ in 32 breast tumor tissues using reverse transcription-quantitative polymerase chain reaction. Furthermore, human epidermal growth factor receptor 2 (HER2) and the Ki-67 status were detected by immunohistochemistry. The results revealed that the ERα and ERβ expression rates recorded were 68 and 65%, respectively. The ERα:ERβ ratio exhibited a decline along with disease progression. ERα and ERβ were found to be negatively correlated with HER2 status but positively correlated with Ki-67. Co-expression of ERα and ERβ was associated with breast cancer aggressiveness, including higher histological grade and positive nodal status, which commonly occur following the menopause. In addition, in cases where ERβ was coexpressed with ERα, HER2 expression was frequently found to be negative, whereas the Ki-67 index was upregulated. These data suggest that ERα and ERβ co-expression may be an indicator of tumor aggressiveness and the sensitivity of hormonal therapy via the downregulation of HER2.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Methodsmentioning

confidence: 99%

ERα and ERβ co-expression: An indicator of aggressive tumors and hormonal sensitivity

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Our results show that HER2 is overexpressed in 13.1% of newly diagnosed breast cancers in Libyan women. This figure is similar to the results obtained in other studies conducted among Middle Eastern and North African populations, where HER2 positivity was estimated at 17.5% in Jordan [15], 18.1% in Tunisia [16], and 18.8% in Saudi Arabia [17]. A more recent study conducted in Saudi Arabia found a higher estimation of HER2 overexpression, with 29.9% positivity among Saudi women with newly diagnosed breast cancer from 2007 to 2013.…”

Section: Survival Analysissupporting

confidence: 89%

HER2/Neu Distribution in Female Breast Cancer in Libya: Correlation with Clinicopathological Features and Survival

O¹,

Jens²,

B³

2021

Int J Cancer Clin Res

View full text Add to dashboard Cite

“…Scoring of Her-2 was done as reported. (14) Normal breast epithelium and capillary were used as positive controls. All of the slides were examined and scored independently by two pathologists without any knowledge of the patient's clinical data.…”

Section: Methodsmentioning

confidence: 99%

Progesterone receptor downregulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer

Zhang

et al. 2012

Cancer Science

View full text Add to dashboard Cite

Breast cancer resistance protein (BCRP) plays a major role in multidrug resistance (MDR). Sequence analysis reveals there is a novel progesterone response element (PRE) in the BCRP promoter, suggesting progesterone receptor (PR) may have a function in the regulation of BCRP expression. We examined the expressions of BCRP, PR, estrogen receptor a (ERa), androgen receptor (AR) and Her-2 in 95 breast cancer samples by immunohistochemistry. Then, to identify the role of PR in the regulation of BCRP expression, two constructs encoding full length BCRP cDNA driven by putative PRE promoter or constitutive CMV promoter were transfected into MCF-7 and MDA-MB-231, respectively. Reverse transcription-polymerase chain reaction (RT-PCR) and western blotting were used to detect the expression of BCRP. Further electrophoretic mobility shift assay (EMSA) was used to verify the nuclear protein-DNA specific binding. We innovatively found that the expression of BCRP negatively related with that of PR and ERa in breast cancer by immunohistochemistry. While at a cellular level, after being treated by progesterone and 17b-estradiol, BCRP mRNA and protein levels were significantly reduced in a concentration-dependent manner in MCF-7/ P-BCRP cells with PR bound to the identified PRE in BCRP promoter. Our results demonstrated that active PR inactived BCRP expression via progesterone-PR complexes binding to PRE in BCRP promoter in breast cancer cells. (Cancer Sci 2012; 103: 959-967) T o date, breast cancer is the most prevalent type of malignant tumor in women, and the multidrug resistance (MDR) is a major obstacle in successful chemotherapy. Breast cancer resistance protein (BCRP) is identified first from drug selected human breast cancer cells (MCF-7/AdrVp).(1) It overexpresses in many cancer cell lines and belongs to the subfamily of G of the ATP-binding cassette (ABC) transporter superfamily.(2-4) It can efflux a variety of chemotheraputic agents including mitoxantrone, topotecan and anthracyclines out of the cell.(5) Therefore, the investigation of mechanism of BCRP expression may bring out better treatment measures for cancer therapy.Recent reports suggest that the BCRP expression may be adjusted at the promoter level by steroid hormones, such as estrogen, progesterone and testosterone via classical pathways, but the data have some conflicts. (6)(7)(8) Hormone-receptor (HR) status has a major role in the prognosis and treatment of breast cancer patients. Estrogen plays an important role in the regulation of progesterone receptor (PR) in both mammary gland and breast cancer. However, there are still 2.00-8.12% of breast cancer patients immunohistochemically with ER-/PR+ and it often occurs in young or middle-aged women. The ER-/PR+ tumors are larger in size and appear more aggressive compared with the group of ER+/ PR+.(9) Therefore, in those ER negative breast cancer cells, the PR expression level should be greatly compromised, which implies that the role of PR remains an enigma.Our group has firstly revealed that toremifen can ...

show abstract

Correlation of hormone receptors with her-2 neu protein expression and the histological grade in invasive breast cancers in a cohort of saudi arabia

Cited by 10 publications

References 20 publications

ERα and ERβ co-expression: An indicator of aggressive tumors and hormonal sensitivity

ERα and ERβ co-expression: An indicator of aggressive tumors and hormonal sensitivity

HER2/Neu Distribution in Female Breast Cancer in Libya: Correlation with Clinicopathological Features and Survival

Progesterone receptor downregulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer

Contact Info

Product

Resources

About